Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 2/20 | 0.34 |
| ▸ | GABRD | O14764 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.34 |
| ▸ | GABRE | P78334 | 2/20 | 0.34 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.34 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19154903 | 1.00 | SLC7A5 (0.44) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL28362973 | 1.00 | SLC7A5 (0.44) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL14177587 | 0.85 | USP2 (0.45) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL22247342 | 0.75 | TSHR (0.45) | GRIK1GRIK2TP53 | |
| SCHEMBL6919782 | 0.73 | TP53 (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6919784 | 0.73 | TP53 (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9468053 | 0.72 | — | — | |
| SCHEMBL6544672 | 0.72 | — | — | |
| SCHEMBL31376432 | 0.72 | — | — | |
| SCHEMBL30011816 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630795-B1 | ENGINEERED ALDOLASE POLYPEPTIDES AND USES THEREOF | ENZYMASTER NINGBO BIO ENG CO LTD (CN) | 2023-07-26 | — | — | EP | disclosed |
| EP-3630795-B1 | ENGINEERED ALDOLASE POLYPEPTIDES AND USES THEREOF | ENZYMASTER NINGBO BIO ENG CO LTD (CN) | 2023-07-26 | — | — | EP | disclosed |
| CN-110869383-B | Engineered polypeptides and their use in the synthesis of beta-hydroxy-alpha-amino acids | 宁波酶赛生物工程有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-110914288-B | Engineered aldolase polypeptides and uses thereof | 宁波酶赛生物工程有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-11512303-B2 | Engineered polypeptides and their applications in the synthesis of beta-hydroxy-alpha-amino acids | ENZYMASTER (NINGBO) BIO-ENGINEERING CO., LTD. (CN) | 2022-11-29 | — | — | US | disclosed |
| EP-3630798-B1 | ENGINEERED ALDOLASE POLYPEPTIDES AND THEIR APPLICATIONS IN SYNTHESIS OF BETA-HYDROXY-ALPHA-AMINO ACIDS | ENZYMASTER NINGBO BIO ENG CO LTD (CN) | 2022-11-23 | — | — | EP | disclosed |
| US-11274287-B2 | Engineered aldolase polypeptides and uses thereof | Enzymaster (Ningbo) Bio-Engineering Co., Ltd (CN) | 2022-03-15 | — | — | US | disclosed |
| US-20210284987-A1 | ENGINEERED POLYPEPTIDES AND THEIR APPLICATIONS IN THE SYNTHESIS OF BETA-HYDROXY-ALPHA-AMINO ACIDS | ENZYMASTER (NINGBO) BIO-ENGINEERING CO., LTD. (CN) | 2021-09-16 | — | — | US | disclosed |
| US-20200123525-A1 | ENGINEERED ALDOLASE POLYPEPTIDES AND USES THEREOF | Enzymaster (Ningbo) Bio-Engineering Co., Ltd (CN) | 2020-04-23 | — | — | US | disclosed |
| CN-110914288-A | Engineered aldolase polypeptide and application thereof | 宁波酶赛生物工程有限公司 | 2020-03-24 | — | — | CN | disclosed |
| CN-110869383-A | Engineered polypeptide and application thereof in synthesis of β -hydroxy- α -amino acid | 宁波酶赛生物工程有限公司 | 2020-03-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274287-B2 | Engineered aldolase polypeptides and uses thereof | DERA, ALDOA, TKT | SLC7A5 171/4885SLC1A3 390/4885SLC1A2 279/4885 |
| US-20200123525-A1 | ENGINEERED ALDOLASE POLYPEPTIDES AND USES THEREOF | DERA, ALDOA, TKT | SLC7A5 171/4885SLC1A3 390/4885SLC1A2 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.